The interlink between AMPK and Nrf2/HO-1 signalling and its potential in treatment of metabolic disease and cancer resurge in the new clinical perspective as a therapeutic option, particularly the cross-activation of these pathways that can control oxidative stress, inflammatory status, and cell metabolism, conferring protective actions against the progression of diseases and improving treatment responses42. The gene discussed is NFE2L2; the disease is Other metabolic disease.